Authors: James Vornov MD, PhD and Jessica Yehnert
Recently, the Medpace stroke team attended ISC (International Stroke Conference). Among the many presentations, one study in particular stood out for its clinical and strategic relevance – OCEANIC-STROKE (NCT05686070). As we’ve seen every year, our understanding of acute stroke treatment strategy deepens, and after a long interval, new guidelines have rolled out from American Society of Anesthesiologists (ASA). What we’ve learned will have an immediate impact on current and planned trials in stroke.
Key Conference Takeaways:
1. Unlocking Advancements in Secondary Prevention: OCEANIC STROKE
OCEANIC-STROKE’s Phase III data has a new standard for secondary prevention. The research tested a novel approach to reducing recurrent ischemic stroke risk by targeting Genetic Factor XI (FXI) – an emerging pathway designed to lower thrombotic risk while preserving hemostatic balance.
The study presented data from a large, global phase III clinical trial evaluating an oral Factor XIa inhibitor in patients with recent non-cardioembolic ischemic stroke or high-risk TIA. Participants were randomized shortly after their index event and treated alongside standard antiplatelet therapy, aligning the trial design closely with real-world clinical practice. The population included patients across major stroke subtypes, reflecting the heterogeneity that Sponsors must account for when designing scalable development programs. Equally important, the trial’s dual focus on efficacy and major bleeding outcomes highlights the industry’s increasing emphasis on demonstrating both clinical benefit and safety differentiation.
From a development standpoint, the trial exemplifies the direction of modern stroke research: large, globally representative populations, pragmatic study designs, and endpoints aligned with regulatory and clinical decision-making. The scale of enrollment and event driven structure underscores the operational complexity required to generate evidence capable of shifting treatment paradigms. Conversations throughout the conference reinforced a shared industry priority – accelerating innovation while maintaining rigorous scientific standards that support regulatory confidence and clinical adoption.
2. Innovation in Standardization & Biomarkers
During ISC, additional advances were highlighted including research on neuroinflammation, immune cell metabolism, and novel biomarkers such as IL-6 and the glucose-to-lymphocyte ratio paving the way for more targeted stroke therapies in the future and biomarker driven early trials.1
An especially compelling theme was how emerging technologies are pushing stroke care toward greater standardization and earlier intervention. A demo booth featured OpenNIHSS2, a wearable system designed to automatically assess the National Institutes of Health Stroke Scale (NIHSS). While the technology is still far from ready for sponsored research, it offers a glimpse into how automated scoring could reduce inter-rater variability and operationalize consistent NIHSS data capture across clinical trials. If validated, tools like this could strengthen endpoint reliability and improve comparability across study sites.
Complementing these advancements in assessment, discussions also highlighted the growing implementation of the Mobile Stroke Unit model3. By bringing imaging, point-of-care testing, and stroke expertise directly to patients in the prehospital setting, mobile units are reshaping the earliest phase of stroke care.
3. CHOICE II & Expanding the Window for Thrombolysis
The CHOICE II trial led the thrombolysis news, confirming in a larger trial from the Barcelona group that adjunctive intra-arterial alteplase after successful endovascular thrombectomy (EVT) significantly improved functional outcomes at 90 days, with no excess in symptomatic intracranial hemorrhage or mortality. This approach targets residual microvascular clots and represents a new frontier in post-thrombectomy care.
Other studies, including OPTION and TRACE-III, explored the use of tenecteplase (TNKase) and continued to provide evidence to extend the window for intravenous thrombolysis up to 24 hours after onset in selected patients. These trials collectively support a broader use of thrombolytics, particularly in patients with imaging evidence of salvageable tissue, and reinforce the role of both alteplase and tenecteplase as first-line agents. However, controversy remains regarding the populations in these trials and their wide applicability where EVT has become standard of care.
4. Neuroprotection Continues to Show Promise
Neuroprotection continues to see trial interest, with new agents such as loberamisal showing encouraging results in improving outcomes when administered within 48 hours of stroke onset. While these findings are promising, neuroprotection remains an area of active research, and larger confirmatory trials are needed before these therapies become standard practice since the pattern has been failure in late stage here.
5. The Debate Continues on EVT for MeVO
Medium vessel occlusion (MeVO) strokes remain a hot topic. Multiple studies presented at ISC 2026 evaluated the efficacy and safety of EVT for MeVO, with results suggesting benefit in select patients but also highlighting the need for more robust data and clear patient selection criteria. The field is moving toward consensus, but further randomized trials are expected before widespread adoption. It seems, based on the guidelines that for the purposes of EVT, we are seeing location stratified as 1) LVO or MeVO in proximal, dominant M2, 2) MeVO in co-dominant M2 and non-dominant M2 or distal vessel occlusion (DVO). The analysis and debate continue about which patients benefit from EVT and where the risk/benefit line lies regarding severity and location.
Where is Stroke Development Research Headed?
Looking ahead, stroke development is moving toward targeted strategies, precision in patient selection, and integrated trial designs spanning acute treatment through long-term prevention.
As therapeutic innovation expands, Sponsors increasingly require partners like Medpace with neuroscience expertise, global operational reach, and the ability to execute complex programs seamlessly across phases. Every year, the landscape changes and deep understanding of current practice is critical for trial success.
Medpace provides the scientific insight, operational execution, and regulatory alignment needed to advance the next generation of stroke therapies from early development.
Making The Complex Seamless® in Stroke Clinical Development
Learn how Medpace leverages its cross-functional neuroscience expertise to streamline study operations and strengthen collaboration between Sponsors, investigators, and vendors in stroke trials in our recent article.
